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Abstract 
BACKGROUND: Disorders in the metabolism of iron in the direction of iron overload are observed not only in 
primary hemochromatosis but also in some chronic liver diseases other aetiology. Elevation of serum iron, ferritin 
and transferrin saturation is reported in nonalcoholic fatty liver disease and alcohol, chronic hepatitis C and liver 
cirrhosis.  
AIM: Aim of the study was to evaluate and compare the frequency of the iron serum markers in patients with 
various chronic liver diseases. 
MATERIAL AND METHODS: The study included a total of 246 persons -186 patients with chronic liver disease 
without cirrhosis (-115 men, women -71; average age of 50.41 ± 12.85, from 23 to 77 years) and 60 healthy 
controls (-30 men, women -30, middle-aged 50.50 ± 11.31, from 29 to 83 years). Medical history, physical 
examination and demographic data including height, weight, laboratory and instrumental studies were performed. 
RESULTS: The highest incidence of elevated serum iron, transferrin saturation and ferritin and decreased serum 
hepcidin found in cases of alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD) and chronic 
hepatitis C (CHC). 
CONCLUSION: Finally, analysis of the changes in serum markers of iron metabolism shows that the difference 
between healthy and sick with liver disease is primarily due to changes in alcoholic and nonalcoholic fatty liver 
disease, particularly steatohepatitis, and chronic hepatitis C. 
 
 
 
 
 
Introduction 
 
The liver is an important organ for the 
homeostasis of the iron. Reticuloendothelial 
macrophages and hepatocytes are the main depots 
more than iron. In the liver is performed the synthesis 
of the hormone hepcidin and thus it became the 
central authority for the regulation of the body's 
reserves of iron [1] [2] [3].  
Disorders in the metabolism of iron in the 
direction of iron overload are observed not only in 
primary hemochromatosis but also in some chronic 
liver disease with another aetiology [4] [5] [6] [7]. 
Increases in serum levels of iron, ferritin, and 
transferrin saturation are reported in nonalcoholic fatty 
liver disease and alcoholic fatty liver disease, chronic 
hepatitis C and liver cirrhosis [8] [9] [10] [11] [12] [13]. 
In recent years, there accumulated a lot of 
new data, some of them contradictory, about the 
clinical significance of serum parameters of iron 
metabolism as surrogate markers of siderosis and 
severity of liver disease [8] [10] [14] [15] [16] [17]. 
There remain open questions regarding the clinical 
significance of serum parameters of iron metabolism 
and hepcidin in various chronic liver diseases and the 
role of some genetic factors and environmental factors 
for organic liver damage during overload syndrome 
iron. 
The study aimed to evaluate and compare the 
frequency of the iron serum markers in patients with 
various chronic liver diseases. 
To implement the above objective we set 
ourselves the following tasks: 
1. To evaluate the change of serum 
parameters of iron metabolism in patients with the 
chronic liver disease compared to healthy subjects 
 2. To carry out comparative serum markers of 
iron metabolism in various chronic liver diseases 
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Material and Methods 
 
Investigated persons  
The study included a total of 246 persons -
186 patients with chronic liver diseases without 
cirrhosis (- 115 men, women - 71; average age of 
50.41 ± 12.85, from 23 to 77 years) and 60 healthy 
controls (men -30 women -30 middle-aged 50.50 ± 
11.31, from 29 to 83 years)  in  seven groups: 
Group I - 38 patients with primary fatty liver 
disease, non-alcoholic (male 20, female 18, mean age 
of 12.45 ± 53.13, from 30 to 76 years) -nonalcoholic 
steatosis (n = 22) and non-alcoholic steatohepatitis (n 
= 16). The diagnosis was based on standard criteria, 
ultrasound evidence of steatosis and histologically 
verified in 22 cases and ruled out other etiologies. 
Group II - 45 patients with alcoholic liver 
disease (31 men, 14 women; mean age of 10.80 ± 
53.42 from 30 to '73) - alcoholic fatty liver (n = 13) and 
alcoholic steatohepatitis (n = 32) with the intake of 
absolute alcohol over 40 g/day, histologically 
confirmed in 39 of them. The diagnosis was based on 
standard criteria and excluded other causes of liver 
damage. 
Group III - 38 patients with chronic hepatitis C 
(21 men, 17 women; mean age of 13.61 ± 52.66 from 
27 to 77 years). All patients with active viral replication 
and the diagnosis were histologically verified in 29 of 
them. 
Group IV - 35 patients with chronic hepatitis B 
(29 men, 6 women, middle-aged 14.40 ± 44.15 from 
23 to 74 years) with evidence of viral replication and 
histologically confirmed the diagnosis in 32 of them. 
Group V -13 patients with chronic hepatitis D 
(7 men, women 6; middle-aged 45.08 ± 9.57, from 30 
to 60 d), serologically demonstrated chronic infection 
in any histologically verified only in 3 of them. 
Group VI -17 patients with autoimmune liver 
disease (male 10, female 7; middle-aged 47.59 ± 
11.52, from 26 to 62 years) - primary biliary cirrhosis 
(n=7) and chronic autoimmune hepatitis (n=10). In all 
patients, the diagnosis was confirmed histologically 
and immunologically. 
All included patients with chronic liver 
diseases no significant comorbidities, interfering with 
the syndrome of iron overload. 
Group VII - 60 healthy volunteers participating 
in clinical trials. All respondents have not a history, 
physical, laboratory, serological (test for HIV, HBV, 
HCV and acute HAV), ECG and ultrasound evidence 
of past or present diseases of the liver and biliary 
system.  
Written informed consent for research is taken 
by all persons involved in the study. 
Methods  
History, physical examination and 
demographic data incl. Height, weight, BMI, 
abdominal circumference. Estimates for daily 
consumption of absolute alcohol are based on 
recalculation in one standard alcoholic unit, which 
equates to about 10-12 g of absolute alcohol.  
They were investigated following standard 
and specific to the disease laboratory parameters, 
incl. Immunological and virological parameters. 
Conventional ultrasound of abdomen and 
pelvis was performed in all respondents, and other 
pictorial or research tools-necessarily. Percutaneous 
or surgical liver biopsy with histologic evaluation of 
grades of steatosis and activity and stage of fibrosis 
was conducted at a total of 142 studied patients with 
chronic liver diseases judged by the criteria of Brunt, 
METAVIR and other standard histological criteria 
(Table 1). 
Table 1: Frequency of histological parameters in patients with 
different groups chronic liver diseases 
Histological 
parameters 
NAFLD Ald  
Chc 
(n=29) 
 
Chb 
(n=32) 
Chb 
 
Hdv 
(n=3) 
Chronic  
autoim
mune 
hepatiti
s 
(n=17) 
Total 
 
(n=142) 
Nas 
(n=6) 
Nash 
(n=16) 
Total 
(n=22) 
As 
(n=7) 
Ash 
(n=32) 
Total 
(n=39) 
Steatosis 
Steatosis  (-) 
(n) 
0 0 0 0 2 2 16 25 2 14 59 
Steatosis 
(+),(n) 
6 16 22 7 30 37 13 7 1 3 83 
1 degree, (n) 1 - 1 - 3 3 10 5 1 1 21 
2 degree  (n) 5 12 17 7 19 26 3 2 0 2 50 
3 degree  (n) - 4 4 - 8 8 - - - - 12 
Activity 
Activity  (-),(n) 6 - 6 7 13 20 0 0 0 1 27 
Activity (+),(n) 0 16 16 0 19 19 29 32 3 16 115 
1 degree , (n) - - 0 - 2 2 5 13 0 5 25 
2 degree , (n) - 10 10 - 11 11 16 13 3 11 64 
3 degree , (n) - 6 6 - 6 6 8 6 0 0 26 
Fibrosis            
Fibrosis  (-
),(n) 
6 1 7 7 1 8 0 6 0 8 29 
Fibrosis 
(+),(n) 
0 15 15 0 31 31 29 26 3 9 113 
1 stage (n) - 8 8 - - 13 14 19 3 9 67 
2 stage (n) - 7 7 - - 12 11 7 0 0 37 
3 stage (n) - - 0 - - 6 4 0 0 0 10 
3 stage (n) - - 0 - - 0 0 0 0 0 0 
 
All patients received the standard treatment 
for the disease. 
The credibility of the results evaluated by the 
following statistical analysis: parametric -t-test for 
paired differences to assess the changes in dynamics; 
-Mann-Whitney nonparametric comparison of 
averages for non-Gaussian distribution of data; 
ANOVA, correlation analysis:  Pearson and 
Spearman, -square test and other (SPSS v.13). The 
results evaluated statistically significant at a threshold 
level of significance p < 0.05. 
 
 
Results 
 
The highest incidence of elevated serum iron, 
transferrin saturation and ferritin and decreased 
serum hepcidin was found in cases with AFLD, 
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NAFLD and CHC.  Increased serum iron was found in 
53% of NAFLD in 64% - at AFLD, 42% - at CHC but 
only 6% in CHB, 8% for CHB+HDV infection and 6% 
in autoimmune liver diseases. Increased serum ferritin 
was reported in 42% for NAFLD in 49% -in AFLD and 
29%-CHC, but only 3% on CHB and 0% in CHB+HDV 
infection and autoimmune liver diseases. Increased 
transferrin saturation was established in NAFLD in 
18%, 36% - at AFLD, 29% - at CHC, 14% - on CHB 
and 8% - at CHB+HDV infection. Decreased serum 
hepcidin was reported in 47% at AFLD, 60% - at 
NAFLD, 53% - at CHC, 26% - on CHB, 8% - at 
CHB+HDV infection and 6% - at autoimmune liver 
diseases. Share distribution in the different groups 
chronic liver diseases with simultaneous increase of 2 
or 3 of serum parameters of iron metabolism is shown 
in Table 2. 
Table 2: Values of iron metabolism in different groups chronic 
liver diseases 
Values of iron 
metabolism 
NAFLD 
(n=38) 
AFLD 
(n=45) 
CHC 
(n=38) 
CHB 
(n=35) 
CHB, 
HDV 
(n=13) 
Autoimm
une liver 
diseases 
(n=17) 
Total 
(n=186) 
 iron  + 
 ferritin (n, %) 
16 
(42%) 
22 
(49%) 
10 
(26%) 
1 
(3%) 
0 
(0%) 
0 
(0%) 
49 
(26%) 
 iron + 
  transferrin 
saturation (n, %) 
6 
(16%) 
16 
(36%) 
9 
(24%) 
2 
(6%) 
1 
(8%) 
0 
(0%) 
34 
(18%) 
  ferritin + 
  transferrin 
saturation (n, %) 
4 
(11%) 
14 
(31%) 
5 
(13%) 
1 
(3%) 
0 
(0%) 
0 
(0%) 
24 
(13%) 
 iron  + 
 ferritin + 
 transferrin 
saturation  (n, %) 
4 
(11%) 
14 
(31%) 
4 
(11%) 
1 
(3%) 
0 
(0%) 
0 
(0%) 
23 
(12%) 
 
The most common abnormal iron metabolism 
found in the group with AFLD, followed by that of CHC 
and NAFLD. In all these cases there was reduced and 
serum hepcidin. 
Serum iron was significantly higher in patients 
with NAFLD compared to controls (Z = -2,2494, P = 
0.013) and CHB (Z = -2,357, P = 0.018), and that at 
AFLD-compared to controls (Z = -4,151, P = 0.0001), 
CHB (Z = -2,125, P = 0.034), CHB+HDV (Z = -4.002, 
P = 0.0001) and autoimmune liver diseases (Z =         
-2,864, P = 0.004) (Figure 1).  
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Figure 1: Serum iron (mmol/l) in different groups 
Significantly higher values were in CHC 
compared to controls (Z = -2,173, P = 0.030) and CHB 
(Z = -2,205, P = 0.027). Values of iron binding 
capacity were significantly higher in patients with 
NAFLD compared to controls (Z =           -5,565, P = 
0.0001) and CHB (Z = -4,736, P = 0.0001) at AFLD - 
compared to controls (Z = -7,844, P = 0.0001), CHC 
(Z = -3,442, P = 0.001), CHB (Z =          -6,578, P = 
0.0001) and autoimmune liver diseases (Z = -2,036, P 
= 0.042) (Figure 2).  
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Figure 2:  Values of iron binding capacity in different groups 
 
Significantly higher values were in CHC 
compared to controls (Z = -4,825, P = 0.0001) and 
CHB (Z = -4,319, P = 0.0001), and in CHB, compared 
to autoimmune liver diseases (Z = -3,921, P = 0.0001) 
as well as in autoimmune liver diseases compared to 
controls (Z = -5,475, P = 0.0001). Ferritin values were 
significantly higher in: NAFLD compared with controls 
(Z = -1,965, P = 0.05), CHB (Z = -3,832, P = 0.0001), 
autoimmune liver diseases (Z = -3,561, P = 0.0001); 
AFLD when compared to controls (Z = -2,953, P = 
0.003), CHB (Z = -3,895, P = 0.0001), and the  
autoimmune liver diseases (Z = -3,740, P = 0.0001 ), 
p = 0.0001); CHC when compared to the CHB (Z = -
2,892, P = 0.004), and the autoimmune liver diseases 
(Z = -2,942, P = 0.003); CHB relative to controls (Z =   
-3,683, P = 0.0001) and autoimmune liver diseases (Z 
= -2,088, P = 0.037) (Figure 3).   
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Figure 3: Values of serum ferritin in different groups 
 
The values of transferrin saturation were 
significantly higher in: NAFLD compared with 
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autoimmune liver diseases (Z = -2,343, P = 0.019); 
AFLD compared with autoimmune liver diseases (Z = 
-3,032, P = 0.002); CHC compared with autoimmune 
liver diseases (Z = -3,035, P = 0.002); CHB compared 
with autoimmune liver diseases (Z = -3,409, P = 
0.001); autoimmune liver diseases and compared to 
controls (Z = -3,450, P = 0.001) (Figure 4).  
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Figure 4: Values of transferrin saturation in different groups  
 
Serum levels of hepcidin were significantly 
lower in patients with NAFLD,  AFLD and CHC in 
comparison to controls (respectively Z = -2,326, P = 
0.02, Z = -3,312, Z = -2,559, P = 0.001 and P = 0.01), 
CHB (respectively Z = -2,122, P = 0.034, Z = -2,991, P 
= 0.003 and Z = -2,295, P = 0.023) and autoimmune 
liver diseases (respectively Z = -2,277, P = 0.023, Z = 
-2.840, P = 0.005 and Z = -2,295, P = 0.022), but no 
statistically significant difference in the comparison 
between them (Figure 5). 
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Figure 5: Values of serum hepcidin in different groups  
 
In all groups chronic liver diseases, serum 
iron, ferritin, transferrin saturation and hepcidin 
showed correlation (r = 0.470-0.875, P = 0.003-
0.0001). Increased serum iron, ferritin, transferrin 
saturation and serum decreased hepcidin, and 
combinations thereof, found more often in metabolic 
steatohepatitis or alcoholic aetiology when comparing 
the cases with steatosis (Table 3). 
Mean serum iron, transferrin and transferrin 
saturation in patients with nonalcoholic and alcoholic 
steatohepatitis showed significantly higher values 
compared with steatosis (respectively Z = -4.155, P = 
0.0001, Z = -3.474, P = 0.001, Z = -4.110, P = 0.0001 
and Z = -3.628, P = 0.0001 (Figures 6, 7, 8).  
Table 3: Values of iron metabolism in NAFLD and AFLD 
Values of iron metabolism NAFLD AFLD 
NAS 
(n=22) 
NASH 
(n=16) 
Total 
(n=38) 
AS 
(n=13) 
ASH 
(n=32) 
Total 
(n=45) 
 Serum  Iron 
(n, %) 
5 
(23 %) 
15 
(94%) 
20 
(53 %) 
3 
(23%) 
26 
(81%) 
29 
(64%) 
 Serum ferritin 
(n, %) 
2 
(9 %) 
14 
(87%) 
16 
(42 %) 
1 
(8%) 
21 
(65%) 
22 
(48.9%) 
 transferrin saturation  
(n, %) 
2 
(9 %) 
5 
(31%) 
7 
(18%) 
1 
(8%) 
15 
(47%) 
16 
(36%) 
 Serum  Iron  + 
 Serum ferritin  (n, %) 
2 
(9 %) 
14 
(87%) 
16 
(42%) 
1 
(8%) 
21 
(66%) 
22 
(49%) 
  Serum  Iron  + 
 transferrin saturation   
(n, %) 
1 
(4%) 
5 
(31%) 
6 
(16%) 
1 
(8%) 
15 
(47%) 
16 
(36% 
 Serum ferritin  + 
 transferrin saturation  
(n, %) 
0 
(0%) 
4 
(25%) 
4 
(11%) 
0 
(0%) 
14 
(44%) 
14 
(31%) 
  Serum  Iron   + 
 Serum ferritin + 
 transferrin saturation   
(n, %) 
0 
(0%) 
4 
(25%) 
4 
(10%) 
0 
(0%) 
14 
(44%) 
14 
(31%) 
 hepcidin (n, %) 5 
(23 %) 
13 
(81%) 
18 
(47%) 
3 
(23%) 
24 
(75%) 
27 
(60%) 
 
Serum hepcidin was significantly lower in 
patients with NASH and ASH compared in groups with 
NAFLD and AFLD, respectively (respectively Z=-
3.252, p=0.001 and Z=2.304, p=0.021) (Figure 9). 
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Figure 6: Values of serum iron in NAFLD and AFLD 
 
 
Discussion 
 
The results of our study show that chronic 
liver diseases detect abnormalities in all serum 
parameters of iron metabolism-elevated serum iron, 
ferritin and transferrin saturation, as well as reduced 
hepcidin compared with healthy individuals. 
Considered changes in parameters of iron metabolism 
separately, the most frequent and approximately 
equally are variations in serum iron and hepcidin, 
followed by those of ferritin and transferrin saturation. 
Deviations from the normal range in healthy 
persons are identified only in serum hepcidin, which 
was reduced in 20% of cases. If we use standard 
laboratory parameters, the frequency of the syndrome 
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of iron overload is estimated at 22% based on 
transferrin saturation above 45%. 
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Figure 7:  Values of iron binding capacity in NAFLD and AFLD 
 
Approximately at this frequency is the 
combined increase in serum levels of the ferritin and 
the iron (26%), as well as the simultaneous increase 
in the iron and transferrin saturation (18%).  
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Figure 8:  Values of serum ferritin in NAFLD and AFLD 
 
Two times lower is the frequency of the 
simultaneously elevated transferrin saturation and the 
ferritin -13%, as well as the simultaneous increases of 
the three serum parameters -iron, transferrin 
saturation and ferritin to -12%. This frequency does 
not change significantly if these combinations are 
added and reduced hepcidin. 
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Figure 9:  Values of transferrin saturation in NAFLD and AFLD 
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Figure 10:  Values of serum hepcidin  in NAFLD and AFLD 
 
This applies both to frequency deviations and 
for their serum levels. At most this is true for serum 
hepcidin. Changes in these groups are more 
apparent, in comparison with those of patients with 
chronic hepatitis B and D, chronic autoimmune 
hepatitis and primary biliary cirrhosis. In all cases of 
combined changes in standard serum markers of iron 
metabolism and all groups HLD is presented and 
reduced hepcidin. We did not find a difference in the 
serum levels of the examined parameters of iron 
metabolism in patients with nonalcoholic and alcoholic 
fatty liver disease. In patients with chronic hepatitis B, 
alone or in combination with chronic hepatitis D, as 
well as autoimmune diseases a change in serum 
markers of iron metabolism is reported only in 
individual cases. 
Our data shows that unlike healthy, in which 
serum iron, ferritin and IBC are higher for men than for 
women, in case of a liver disease gender difference in 
the level of serum iron and IBC disappears. 
Deviations of the serum indicators of iron metabolism 
were more pronounced with age (predominantly in HH 
C) and increased BMI. Relationship with BMI was 
mainly at the expense of patients with NAFLD and HH 
C. Only in patients with NAFLD all indicators were 
more obviously deviated in obesity. This can be 
explained by the relationship of these diseases with 
insulin resistance [17] [18]. 
For the first time, we found different 
correlations between serum parameters of iron 
metabolism in healthy patients and those with the 
disease. While in healthy individuals only have a 
positive relationship between the level of iron and IBC 
and feedback between serum hepcidin and transferrin 
saturation, then in HLD as a whole and individual 
subgroups of liver disease serum levels of iron, IBC, 
ferritin, transferrin saturation and hepcidin showed a 
strong correlation. 
In HLD is proved a link between indicators 
reflecting liver damage and liver function and serum 
parameters of iron metabolism. We found a 
correlation between serum markers of iron 
metabolism and liver enzymes AST, ALT and GGT, as 
the abnormalities were higher in groups with diverted 
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indicators of iron metabolism in comparison to the 
group with normal levels. Further-more serum 
markers of iron metabolism correlated with total 
bilirubin and direct bilirubin, prothrombin time, and 
platelet count. These results confirm established by 
other authors interconnections between the 
parameters of the syndrome of iron overload and liver 
enzymes and liver function [19] [20] Also, we have 
established a link with IgA. The advantage of our 
study is that we proved the greatest relationship of 
these indicators with the global assessment of 
severity of liver disease-index weight of liver damage. 
Serum iron, IBC, ferritin and transferrin saturation 
increases with TLD and values of hepcidin-reduces. 
We proved and their relationship with HDL-
cholesterol, triglycerides and glucose. All correlations 
are determined primarily by changes in patients with 
NAFLD and ALD. Also, in patients with NAFLD and 
ALD, we found another correlation between AF and 
albumin. The relationship between KKLI-indicator to 
assess the severity of alcoholic liver disease and the 
serum parameters of iron metabolism is determined 
by patients with alcoholic steatohepatitis. In patients 
with proven HH C, we proved a connection mainly 
with indicators for severity of liver damage-total and 
direct bilirubin, albumin and prothrombin index. 
In our study, we examined various liver 
diseases, and we examined the overall changes in 
iron metabolism in the control group of healthy 
persons and in between them. In NAFLD is often 
increased serum iron (53%), followed by a decrease 
in serum hepcidin (47%) and elevated ferritin (42%), 
and about 2 times less frequently elevated transferrin 
saturation (18%). The combined standard deviation of 
serum markers of iron metabolism is most often the 
simultaneous increase in serum iron and ferritin-42%, 
followed by increases in serum iron and HT-16%. In 
11% had elevated serum iron, ferritin and HT. Our 
results show that the incidence of the syndrome of 
over-saturation with iron, as measured according to 
the standard serum markers is 18% based on the 
increased NT and 11%-based on changes in any 
serum markers. The higher incidence of abnormal 
serum iron and ferritin corresponds to the hepcidin, 
but can be explained by non-specific changes related 
to the underlying disease. 
In ALD increased serum iron (64%) together 
with reduced serum hepcidin (60%) are the most 
common abnormalities. Ferritin was promoted to ½ of 
the cases (49%). And in this condition as in NAFLD 
transferrin saturation above 45% is the rare deviation-
36%. The simultaneous increase in serum iron and 
ferritin was 48%, but the combined tolerances of 
increased serum iron and LT, as well as increased 
iron, transferrin and HT,  are the most common in 
alcoholic aetiology, respectively in 36% and 31%. The 
incidence of the syndrome of over-saturation with iron 
was 36% by elevated HT and 31%-based on changes 
in any serum markers. This frequency is the highest in 
comparison with all other chronic liver diseases, and it 
is about 2 to 3 times greater in comparison with 
patients with NAFLD. Here, as in NAFLD incidence of 
abnormal serum iron corresponds to the hepcidin, but 
about half of these cases can certainly be considered 
an overload of iron based on changes in the standard 
serum markers of iron metabolism. It is more 
pronounced changes in hepcidin to meet in earlier 
changes in the liver before a heavy load of iron.  
Interest is the comparison of the results in 
patients with steatosis and steatohepatitis inside 
NAFLD groups and ALD and between them. We 
found more pronounced deviations in all serum 
markers of iron metabolism in both non-alcoholic and 
alcoholic steatohepatitis when compared to cases with 
steatosis, and no difference between patients with 
NAD and ALD, and between those with NASH and 
ASH. The values of serum iron parameters of 
metabolism in patients with nonalcoholic steatosis and 
alcohol were close to the controls and other groups 
HLD, but transferrin saturation in them is higher. The 
values of the parameters of iron metabolism in 
alcoholic and nonalcoholic steatohepatitis are highest. 
Increased serum iron, ferritin, transferrin 
saturation and decreased serum hepcidin, as well as 
a combination between them, we found more often in 
steatohepatitis with alcohol or metabolic aetiology 
compared to cases with steatosis. Thus the frequency 
of the overload of iron in NASH increases to 31% (on 
NT) and 25% (all indices), and in ASH-respectively 
47% and 44%. The increase in serum iron and ferritin 
and reduction of hepcidin were found in over two-
thirds of those surveyed with NASH and ASH. 
In HH C deflected (low), the most are serum 
hepcidin (53%), followed by increased serum iron 
(42%). Elevated transferrin saturation and ferritin are 
detected equally-29%. Differences in the rate of 
change of the different parameters are less in 
comparison to the alcoholic and nonalcoholic fatty 
liver disease. Almost 2 times less frequent is the 
combination of increased serum iron and increased 
ferritin. On the other hand at the same time, an 
increase in the iron and HT (24%), ferritin and HT 
(13%) and the deviation in all the indicators (11%) are 
close to that of NAFLD. The frequency of iron 
overload by elevated HT is 29% and 11%-13%-based 
on the above latter two combinations. 
Unlike HH C in HH B increased serum iron is 
found only in 2 of 35 patients (6%) and in the same 
proportion (1 out of 13 patients-8%)-for chronic HDV 
infection, and the ferritin-in 1 patient (3%), and none 
of the patients with HHD. At higher levels, we found 
elevated transferrin saturation (14%) and decreased 
serum hepcidin (26%). However, this frequency 
corresponds to that in healthy individuals. Variation in 
these indicators we found in only 1 case (8%) with 
accompanying HDV infection. A combination of 
increased iron with increased HT we reported in 2 
patients with HH B (respectively 1 patient with HHD), 
and when one of them combined with the rest of the 
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parameters. Accordingly to the above changes in 2 
patients with HH B and 1-with HHD maintained 
overload with iron according to the increased 
transferrin saturation, and in one of the patients with 
HH B-and according to the combination of the 
remaining markers. 
In autoimmune diseases, increased serum 
iron we found in only 1 out of 17 tested cases (6%) 
diagnosed with PBC. In another case, we found 
reduced serum hepcidin (6%). Data for immune-
mediated liver diseases are extremely small. Similar 
to our observation, it is reported a very low incidence 
of biliary cirrhosis [16] [21]. 
In conclusion, the analysis of data from our 
study shows changes in every serum marker of iron 
metabolism, including reducing of serum hepcidin in 
nonalcoholic and alcoholic fatty liver disease, and 
chronic hepatitis C in comparison with healthy 
persons, and other chronic liver diseases associated 
with HBV, HDV or autoimmune pathogenesis. It is 
proved a strong correlation between them. The 
syndrome of iron overload correlates mainly with liver 
enzymes, liver function tests, and metabolic 
parameters. None of the surrogate serum markers of 
iron overload in chronic liver disease does reflect fully 
and accurately haemosiderosis. However, we 
recommend the evaluation to be carried out by 
transferrin saturation above 45%, alone, especially 
NAFLD or together with the increased transferrin-in 
alcoholic liver disease and chronic hepatitis C. Thus, 
with the highest probability is confirmed iron overload. 
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